WIXLIB

H1-22 Interim Results24th May 2022Giulio CerroniCEOGrant NashCFO

Nonregulated DisclaimerThis presentation is incomplete without reference to, and should be viewed solely in conjunction with, the oral briefing which accompanies it. Theinformation in this presentation is subject to updating, revision and amendment. The information in this presentation, which includes certaininformation drawn from public sources does not purport to be comprehensive and has not been independently verified. It has been prepared andissued by and is the sole responsibility of the Company.No reliance may be placed for any purpose whatsoever on the information contained in this presentation or any assumptions made as to itscompleteness. No representation or warranty, express or implied, is given by the Company, any of its subsidiaries or any of its advisors, directors,officers, employees or agents, as to the accuracy, reliability or completeness of the information or opinions contained in this presentation or inany revision of the presentation or of any other written or oral information made or to be made available to any information or opinions (whichshould not be relied upon) and no responsibility is accepted for any errors, misstatements in or omissions from this presentation or for any losshowsoever arising, directly or indirectly, from any use of this presentation or its contents. The information and opinions contained in thispresentation are provided as at the date of this presentation and are subject to change without notice.In particular, this presentation may contain certain forward-looking statements that are subject to the usual risk factors. Whilst the Companybelieves the expectations reflected herein to be reasonable in light of the information available to them at this time, the actual outcome may bematerially different owing to factors beyond the Company’s control or with in the Company’s control where, for example the Company decideson a change of strategy. Accordingly no reliance may be placed on the figures or other indications contained in any such potential forward-lookingstatements. No representation or warranty of any kind is made with respect to the accuracy or completeness of the financial projections or otherforward-looking statements, any assumptions underlying them, the future operations or the amount of any future income or loss.The content of this presentation has not been approved by an authorised person within the meaning of the Financial Services and Markets Act2000 (“FSMA”). This presentation does not constitute or form part of any offer or invitation to see, or any solicitation of any offer to purchase orsubscribe for or otherwise acquire, any securities in the Company in any jurisdiction or any other body corporation or an invitation or aninducement to engage in investment activity under section 21 of FSMA, nor shall it or any part of it form the basis of or be relied on in connectionwith any contract therefore. This presentation does not constitute an invitation to effect any transaction with the Company or to make use of anyservices provided by the Company. Reliance on the information contained in this presentation for the purposes of engaging in any investmentactivity may expose the investor to a significant risk of losing all of the property or assets invested. Any person who is in any doubt about theinvestment in business to which this presentation relates should consult a person duly authorised for the purposes of FSMA who specialises in theacquisition of shares and other securities.By attending the presentation or reading or accepting this document you agree to be bound by the foregoing limitations.IXICO plc is incorporated in England with registered number 3131723 and registered address 15 Long Lane, London, EC1A 9PN.2PUBLIC IXICO plc 2022

Precision in neuroscienceAIM: IXI

Our purpose is to advance medicine and human health by delivering intelligentinsights in neuroscience – differentiated with proprietary AI Analytics. Neurological research is the 2ndlargest development area for newdrugs after oncology[1]. Dementia is the only major cause ofdeath we can’t slow down or cure[2]. 1.3 trillion worldwide healthcare costin 2019 of dementia[3]. Aging population: Tripling of peoplewith dementia to 130million between2015 and 2050[4] Likelihood of a phase I clinical trialdrug candidate achieving approval isjust under 8% with Neurology atunder 6%.[5] Neurological drug developmenttimelines are amongst the longest inthe industry at over 11 yearsOur technology services provide data-driven insights to enable the design ofmore efficient clinical trials to increase the likelihood of approval of innovative,safe therapies to market, sooner.[1] PhMRA Biopharmaceutical research industry, 2016 profile [2] World dementia council, Defeating dementia: the road to 2025 [3] World Health Organisation Dementia report Sep-21[4] The World Alzheimer Report 2018, ADI,London [5] Biotechnology innovation organiszation, pharma intelligence informa, Quantitative Life Sciences: Clinical development success rates and contributing factors 2011-20204PUBLIC IXICO plc 2022

2017-2022 Growth StrategyFocus ondelivering scaleand operationalexcellencePenetrationof clinical trialsmarket in selecttherapeuticareasTarget earlyphase to growinto later clinicalphasesInnovateNext generationData platformand AI dataanalyticsEnhanceorganic growththroughselectivepartnershipsand M&A to deliver sustained, double- digit profitability5PUBLIC IXICO plc 2022

Track record of delivery Raised c. 5m early in 5 year period at 28p to drive double digit growth and path to profitability 20% 5 year revenue CAGR with 20% gross margin accretion More than doubling revenues from 4.1m in 2017 to 9.2m in 2021 IXICO has increased project diversification by 50%, and increased CNS therapeutic indications by 100%, across the last 2 years Established a global network of over 900 imaging centres across 37 countries A rapid EBITDA transition from 1.4m loss (2017) to 1.7m profit (2021) Balance sheet growth from 2.7m (2017) to 11.5m (H1-2022), 30% CAGR Cash at 31st March 2022 of 5.8m, operating cash generative and debt free. .Expanded operational capabilities whilst investing to scale6PUBLIC IXICO plc 2022

Investing to scale: innovation, technology and infrastructure Proven resilience, quality and reliability : 21 CFR11 & GCP compliant end-to-end Trial Tracker imaging platform. Demonstrated the resilience of our centralised remote service model throughout the Covid-19 pandemic Next generation, Microsoft Azure cloud-based Trial Tracker development programmeProven operational capabilities to scale Doubling the number of active client projects across all phases of clinical development to over 30 today. Successful delivery of PIII studies; including world’s largest global HD PIII trialProven science & innovation leadership: Supported multiple exploratory disease consortia (e.g. GAP, AMYPAD, DPUK, EPAD, ADNI, C-PATH, FARA,TRACK HD) Substantial increase in access to disease specific data assets Rapidly expanding portfolio of proprietary AI driven analytics tools. Launch of next generation IXIQ.Ai Current biopharma client projects provide springboard for long term growth7PUBLIC IXICO plc 2022

2022-2027: Precision analytics growth strategyFurther differentiating IXICO’s offering by addressing client focus on enhancing objectivity,precision and efficiency in clinical trialsBuildInnovatePenetrateBridgeEnhance commercialreach build on dataassets iCRO scale leading neuroAI biomarkerportfolio early phasetrials to growinto laterclinical phases the clinicaltrial to clinicaldiagnosticdivide. organic growththroughpartnershipsand M&A Investing to scale with strategy to deliver8PUBLIC IXICO plc 2022

Precision Analytics in Neuroscience Drug development programs employing patient pre-selection biomarkers show double likelihood of approval at just under 16%[1] Move towards precision medicine in CNS clinical trials is driving increasing use of imaging biomarkers IXICO’s LEAP and IXIQ.Ai measures are clinically validated for biomarker-based patient selection Systematic stratification enables smaller, shorter, lower cost trials or, alternatively, increased power to detect subtle treatment changes Further development of IXICO’s proprietary deep learning AI platform enables multi-modal predictive modelling to increase accuracy indisease staging and diagnosis 30% reduction in trial size using IXICO model*100%90%80%70%60%50%RadiologistA LEAPA N IXICO Disease Model[1] Biotechnology innovation organiszation, pharma intelligence informa, Quantitative Life Sciences: Clinical development success rates and contributing factors 2011-2020*IXICO analysis on ADNI in Mild Cognitive Impairment (MCI)9PUBLIC IXICO plc 2022

FDA approval of Biogen’s Aducanumab breaks 18 year stalemate inAD drug developmentBiogen: Aduhelm (aducanumab) First Disease Modifying Treatment for Alzheimer’s Ongoing confirmatory trial, ENVISION Requirements for continued safety monitoring of those patients on drug, post marketingNext in line amyloid targeting drugs in late stage development Biogen and Eisai’s follow-up Lecanemab; Roche’s Gantenerumab; and Eli Lilly’s DonanemabPlus increased diversification in drug targets being pursued in AD. .Renewed biopharma interest in AD represents a significant growth opportunity for IXICO10PUBLIC IXICO plc 2022

FinancialsAIM: IXI

Impact of client trial failures reflected in H1-financialsRevenues ( m)Gross Margin (%)EBITDA ( -17 H1-18 H1-19 H1-20 H1-21 H1-22̶12Revenues in H1-22 reflectimpact of client trial failuresand COVID-19̶Market opportunity unchanged̶Focus on rebuilding orderbook, but takes timeH1-17 H1-18 H1-19 H1-20 H1-21 H1-22-0.7H1-17 H1-18 H1-19 H1-20 H1-21 H1-22̶Strong gross margins̶Positive EBITDA̶H1-22 reflects revenue contractionand greater proportion of earlyphase trials̶14% EBITDA margin̶Profits being reinvested for longterm growthPUBLIC IXICO plc 2022

Investing for the long term, whilst managing the short termR&D expenditure ( m)2.0S&M expenditure ( 50.71.00.625%15%13% 13%11% 12%0.650%5%0.30.40.90.70.5-5%H1-17 H1-18 H1-19 H1-20 H1-21 H1-22% of RevenuesS&M ( M)45%̶̶ 1.0m R&D capitalised; primarily innew data analysis platform andanalysis pipelinesRestructure of commercialteam in H1-22̶COVID-19 impact on travel andconference attendance̶ 5M contracts signed year todate across diversified clientsand therapeutic .4-H1-17 H1-18 H1-19 H1-20 H1-21 H1-22G&A( M)% of RevenuesFocused investment in R&DUnderpins enhanced value provisionto client CNS trials and scalability-51%30%0.2 10%0.32.040%0.4 20%̶̶13Expensed R&D ( m)0.820%60%15%H1-17 H1-18 H1-19 H1-20 H1-21 H1-22Capitalised R&D ( m)1.045%35%G&A expenditure ( m)̶% of RevenuesControlled G&A investmentsPUBLIC IXICO plc 2022

Strong balance sheet supports investment for long term growthNet Assets ( m)Cash ( m)7.97.37.911.2 017 2018 2019 2020 2021 H1-222017 2018 2019 2020 2021 H1-2214Closing Order Book ( m)2017 2018 2019 2020 2021 H1-22̶ 5.8m cash position̶ 11.5m net asset position̶Significant set back in order book̶ 0.2m operating cash inflow̶̶̶ 1.1m investment in capital assetsReflects investments for the longterm3 largest client trials ceased acrosstwelve months ( 12.8m contracts)̶Debt free̶Working capital of 7.5m̶Order book diversification and clientnumbers increased̶Strong position to supportcontinued investment plans̶Will take time to rebuild to 2020levels.PUBLIC IXICO plc 2022